<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00745199</url>
  </required_header>
  <id_info>
    <org_study_id>4146</org_study_id>
    <nct_id>NCT00745199</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus</brief_title>
  <official_title>Phase II Study of the Effect of Oral Cromolyn Sodium on Uremic Pruritus and Serum Tryptase Levels of Hemodialysed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pruritus is a major disorder among the skin derangements in advanced renal failure. Recent
      information suggests that interactions between dermal mast cells and distal ends of
      nonmyelinated C fibers may be important in the precipitation and regulation of the sensory
      stimuli.Patients having uremic pruritus have been noted to have increased levels of plasma
      histamine and tryptase as well as increased numbers of dermal mast cells.Cromolyn sodium is a
      mast cell stabilizing agent that inhibits degranulation of mast cells and the release of
      histamine, tryptase, and leukotrienes. It is hypothesized that oral cromolyn sodium may
      attenuate uremic pruritus by decreasing serum tryptase level.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pruritus</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum tryptase level</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on hemodialysis with pruritus, receiving cromolyn sodium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients on hemodialysis with pruritus, receiving placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients on hemodialysis but without pruritus who do not receive any treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cromolyn sodium</intervention_name>
    <description>oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients &gt; 18 yo suffering from pruritus for at least 6 weeks, and who
             have not responded to other drugs

          -  Willing and able to give informed concent

        Exclusion Criteria:

          -  Known dermatologic, liver, metabolic disease, or any other disease or condition other
             than ESRD that causes pruritus

          -  Lactase deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghazal Vessal, PharmD, BCPS</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Mahdi Sagheb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saman Shilian, Pharm student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University of Medical sciences, Nemazi and Faghihi Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>71345</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2008</study_first_submitted>
  <study_first_submitted_qc>September 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2008</study_first_posted>
  <last_update_submitted>August 17, 2009</last_update_submitted>
  <last_update_submitted_qc>August 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr.Ghazal Vessal PharmD, BCPS</name_title>
    <organization>Shiraz University of Medical Sciences</organization>
  </responsible_party>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Cromolyn Sodium</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Tryptase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cromolyn Sodium</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 17, 2012</submitted>
    <returned>January 22, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

